Company Overview
| Stock Name | Jacobson Pharma |
|---|---|
| Stock Code | 02633 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 非專利藥及中成藥的開發、生產、市場推廣及銷售,為香港最大的非專利藥公司,產品涵蓋心血管科、中樞神經系統科、腸胃科、口服糖尿藥及呼吸系統科等專科藥,以及保濟丸、飛鷹活絡油等中成藥。 |
| Listing Date | 2016-09-21 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港九龍觀塘道388號創紀之城1期1座23樓2313-18室 |
| Business Address (Hong Kong) | 香港九龍觀塘觀塘道388號創紀之城1期1座23樓2313-18室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.jacobsonpharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 1.50 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.01 / shares |
| Offer Period | 2016-09-08 to 2016-09-13 |
| Global Offering Shares | 437,500,000 shares |
| HK Public Offer Shares (Initial) | 43,752,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 393,748,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,750,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 4.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 656,250,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 2.16B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +334% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約152.7百萬港元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 67,100,000 |
| Listing Expenses / Funds Raised | ~10.22% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
HKD
Income Statement
| Item | 2014-03 | 2015-03 | 2016-03 |
|---|---|---|---|
| Revenue | 926,181 | 947,591 | 1,083,856 |
| Cost of sales | -501,339 | -562,883 | -596,101 |
| Gross profit | 424,842 | 384,708 | 487,755 |
| Other income and gains, net | 65,172 | 6,005 | -465 |
| Selling and distribution expenses | -97,974 | -105,061 | -133,807 |
| Administrative expenses | -169,123 | -146,810 | -167,963 |
| Operating profit | 222,917 | 138,842 | 185,520 |
| Net finance costs | -5,969 | -2,707 | -2,523 |
| Profit before tax | 216,948 | 136,135 | 182,997 |
| Income tax expense | -32,247 | -22,157 | -30,335 |
| Profit for the year | 184,701 | 113,978 | 152,662 |
| Profit attributable to owners | 172,357 | 101,904 | 145,610 |
Balance Sheet
| Item | 2014-03 | 2015-03 | 2016-03 |
|---|---|---|---|
| Cash and cash equivalents | 131,492 | 70,258 | 82,925 |
| Trade and bills receivables | 142,740 | 148,795 | 209,957 |
| Inventories | 160,368 | 169,087 | 196,915 |
| Total current assets | 444,940 | 394,035 | 499,989 |
| Total assets | 1,456,809 | 1,705,211 | 1,822,050 |
| Total current liabilities | 488,914 | 650,238 | 816,835 |
| Total liabilities | 539,822 | 698,576 | 865,905 |
| Total equity | 916,987 | 1,006,635 | 956,145 |
| Equity attributable to owners | 877,894 | 957,343 | 906,882 |
| Interest-bearing borrowings | 299,576 | 475,629 | 439,335 |
Cash Flow Statement
| Item | 2014-03 | 2015-03 | 2016-03 |
|---|---|---|---|
| Net cash from operating activities | 150,272 | 161,754 | 221,450 |
| Net cash from investing activities | -126,529 | -390,971 | -133,723 |
| Net cash from financing activities | -8,747 | 160,853 | -67,586 |
| Net increase in cash | 14,996 | -68,364 | 20,141 |
| Purchase of PP&E | -200,391 | -339,612 | -134,143 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 1.68 |
|---|---|
| First Day Open | HK$ 1.58 |
| First Day Change | 12.00% |
| First Day Volume | 107290000.0 |
| First Day Turnover | 173359000.0 |
| Use of Proceeds | 1、約45%(或270.5百萬港元)用作收購事項;
2、約18%(或108.2百萬港元)用作有關收購、拓展、精簡或提升我們的制造廠房、房產、設施或產能的資本投資;
3、約15%(或90.2百萬港元)用作為專門非專利藥進行生物等效性臨床研究;
4、約12%(或72.1百萬港元)用作在未來五年加大我們的銷售、市場推廣及廣告宣傳力度,以提升品牌的認可度及加強我們產品及業務的品牌忠誠度;
5、約10%(或60.1百萬港元)用作營運資金及其他一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中银国际亚洲有限公司 CE AET863
Joint Bookrunners (1)
中银国际亚洲有限公司 CE AET863
Joint Lead Managers (1)
中银国际亚洲有限公司 CE AET863
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | New Heritage Healthcare Limited | 49,998,000 HKD | — | 1.90% | — | 6 months | 2017-03-21 |
| 2 | 香港荣华药业集团有限公司 | 79,998,000 HKD | — | 3.00% | — | 6 months | 2017-03-21 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 岑廣業 | — |
| Company Secretary | 黃偉明 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 緊隨全球發售完成後,Kingshill及Longjin為一致行動方,合共持有本公司約57.58%權益;岑廣業先生透過Kingshill、Queenshill等合共持有約74.78%權益。 |
|---|




